Fig. 6

Therapeutic efficacy of piggyBac-NKG2D.CAR-NK cells combined with anti-CD73 antibody blockade for CD73⁺ tumor targeting in a xenograft mouse model. a Schematic diagram showing the in vivo treatment program. b Tumor growth curves during CAR-NK and anti-CD73 adoptive transfer immunotherapy. c Changes of body weights of the mice during the experiment. d Immunohistochemical staining for CD56⁺ NK-92 cells in tumors (arrows; magnification × 200; bar = 100 μm). e The corresponding quantitative analysis results of human CD56⁺ NK-92 cells. Data are presented as the mean ± SEM (n = 5). *P < 0.05